See more : Aarti Drugs Limited (AARTIDRUGS.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Neoleukin Therapeutics, Inc. (NLTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Neoleukin Therapeutics, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- CNOOC Limited (CNU.TO) Income Statement Analysis – Financial Results
- Absci Corporation (ABSI) Income Statement Analysis – Financial Results
- eFUEL EFN CORPORATION (EFLN) Income Statement Analysis – Financial Results
- Greenbelt Resources Corporation (GRCO) Income Statement Analysis – Financial Results
- Sumiseki Holdings,Inc. (1514.T) Income Statement Analysis – Financial Results
Neoleukin Therapeutics, Inc. (NLTX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.neoleukin.com
About Neoleukin Therapeutics, Inc.
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 6.00K | 451.00K | 0.00 | 25.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 6.00K | 451.00K | 0.00 | 25.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 41.13M | 39.16M | 24.34M | 4.42M | 41.79M | 36.27M | 28.38M | 15.80M | 18.08M | 7.54M | 6.05M |
| General & Administrative | 17.97M | 21.54M | 17.21M | 18.83M | 15.84M | 14.85M | 9.26M | 5.54M | 4.30M | 1.78M | 1.64M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.97M | 21.54M | 17.21M | 18.83M | 15.84M | 14.85M | 9.26M | 5.54M | 4.30M | 1.78M | 1.64M |
| Other Expenses | -42.00K | 6.00K | -44.00K | -8.00K | -445.00K | -39.00K | -43.00K | -369.00K | -254.89K | 0.00 | 64.03K |
| Operating Expenses | 59.10M | 60.70M | 41.55M | 23.24M | 57.62M | 51.12M | 37.65M | 21.34M | 22.38M | 9.38M | 7.68M |
| Cost & Expenses | 59.10M | 60.70M | 41.55M | 23.24M | 57.62M | 51.12M | 37.65M | 21.34M | 22.38M | 9.38M | 7.68M |
| Interest Income | 1.58M | 19.00K | 490.00K | 1.54M | 1.56M | 998.00K | 619.00K | 0.00 | 0.00 | 26.32K | 0.00 |
| Interest Expense | 1.58M | 0.00 | 0.00 | 1.00K | 4.00K | 4.00K | 1.00K | 99.00K | 461.59K | 42.92K | 9.47K |
| Depreciation & Amortization | 2.61M | 2.28M | -13.84M | 49.59M | 1.04M | 940.00K | 644.00K | -421.00K | 135.95K | 59.57K | 130.78K |
| EBITDA | -56.49M | -60.70M | -47.56M | -21.37M | -31.51M | -50.16M | -37.07M | -21.71M | -24.38M | -9.68M | -7.53M |
| EBITDA Ratio | 0.00% | -1,011,633.33% | -10,546.34% | 0.00% | -126.02% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -59.10M | -60.70M | -33.73M | -70.96M | -32.62M | -51.12M | -37.65M | -21.34M | -23.57M | -9.38M | -7.66M |
| Operating Income Ratio | 0.00% | -1,011,633.33% | -7,478.49% | 0.00% | -130.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.54M | 6.00K | 7.83M | 1.52M | 1.04M | 936.00K | 643.00K | -520.00K | 487.60K | 641.24K | -9.47K |
| Income Before Tax | -57.56M | -60.69M | -33.28M | -69.44M | -31.59M | -50.18M | -37.00M | -21.86M | -24.03M | -8.73M | -7.67M |
| Income Before Tax Ratio | 0.00% | -1,011,533.33% | -7,378.49% | 0.00% | -126.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.54M | -2.28M | -8.32M | -7.00K | -1.04M | -940.00K | -644.00K | 421.00K | -222.00 | -5.04K | 42.29K |
| Net Income | -56.02M | -58.42M | -24.96M | -69.44M | -31.59M | -50.18M | -37.00M | -21.86M | -23.82M | -9.30M | -12.14M |
| Net Income Ratio | 0.00% | -973,583.33% | -5,533.48% | 0.00% | -126.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.01 | -1.06 | -0.48 | -2.57 | -1.34 | -2.14 | -1.96 | -1.73 | -2.75 | -0.93 | -2.08 |
| EPS Diluted | -1.01 | -1.06 | -0.48 | -2.57 | -1.34 | -2.14 | -1.96 | -1.73 | -2.75 | -0.93 | -2.08 |
| Weighted Avg Shares Out | 11.04M | 11.01M | 10.37M | 5.41M | 4.70M | 4.69M | 3.78M | 2.53M | 1.73M | 1.17M | 1.17M |
| Weighted Avg Shares Out (Dil) | 11.04M | 11.01M | 10.37M | 5.41M | 4.70M | 4.69M | 3.78M | 2.53M | 1.73M | 1.17M | 1.17M |
Aquinox (NLTX) Moves to Buy: Rationale Behind the Upgrade
Aquinox (NLTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neoleukin Therapeutics Receives Clinical Hold Letter from U.S. FDA Related to CMC Assay Development for NL-201
SEATTLE, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that on January 7, 2021, it received a clinical hold letter from the U.S. Food...
Neoleukin Therapeutics Announces Submission of Investigational New Drug Application for NL-201 De Novo Protein Immunotherapy Candidate for Cancer
SEATTLE, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the submission of an Investigational New Drug (IND) Application with the U.S. Food and Drug...
Neoleukin Therapeutics Announces Participation in Piper Sandler 32nd Annual Virtual Healthcare Conference
SEATTLE, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat at the...
Neoleukin Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference
SEATTLE, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the Stifel 2020 Virtual Healthcare...
Neoleukin Therapeutics Presents Preclinical Combination Data for NL-201 at Society for Immunotherapy of Cancer's 35th Anniversary Annual Meeting (SITC 2020)
- NL-201 enhances activity of checkpoint inhibitors and tumor-targeting antibodies and increases immune cell stimulation -
Neoleukin Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Update
- NL-201 IND submission anticipated by year end 2020 -
Neoleukin Therapeutics Announces Publication in Science of De Novo Protein Decoys that Block COVID-19 Infection In Vitro and Protect Animals In Vivo
- I ntranasal administration of NL-CVX1 protects hamsters from lethal SARS-CoV-2 infection –
Sabar
Candidato
Online Movie Ticketing Service Market Analysis Highlights the Impact of COVID-19 (2020-2024) | Increased Use of Mobile Applications to boost the Market Growth | Technavio
The Global Online Movie Ticketing Service Market will grow by USD 14.8 bn during 2020-2024
Source: https://incomestatements.info
Category: Stock Reports